4,6-二羟基烟酸 | 5466-62-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4,6-二羟基烟酸
• 英文名称: 4,6-Dihydroxy-pyridin-carbonsaeure-(3)
• 英文别名: 4,6-dihydroxy-nicotinic acid；4,6-Dihydroxy-nicotinsaeure；4,6-Dihydroxynicotinic acid；4-hydroxy-6-oxo-1H-pyridine-3-carboxylic acid
• CAS: 5466-62-6
• 化学式: C₆H₅NO₄
• mdl: MFCD00234168
• 分子量: 155.11
• InChiKey: QJLHSJRQOWSNMD-UHFFFAOYSA-N

物化性质

• 熔点：
  309-311°
• 沸点：
  327.6±42.0 °C(Predicted)
• 密度：
  1.708±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4,6-二羟基烟酸 在 氨 作用下， 生成 4,6-二氯烟腈
  参考文献：
  名称：

  The Synthesis of 4-Amino-2,5-diphenylthiazole

  摘要：

  DOI：

  10.1021/ja01625a090
• 作为产物：
  描述：

  4,6-二羟基烟酸乙酯 在 氢氧化钾 作用下， 生成 4,6-二羟基烟酸
  参考文献：
  名称：

  Errera, Gazzetta Chimica Italiana, 1898, vol. 28 I, p. 489

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF JAK<br/>[FR] INHIBITEURS DE JAK
  申请人：PORTOLA PHARM INC

  公开号：WO2010129802A1

  公开（公告）日：2010-11-11

  The present invention is directed to compounds of formula (I) and tautomers and pharmaceutically acceptable salts thereof which are selective inhibitors of JAK. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK activity, and methods to prevent or treat a number of conditions mediated at least in part by JAK activity.

  本发明涉及式(I)的化合物及其互变异构体和药学上可接受的盐，这些化合物是JAK的选择性抑制剂。本发明还涉及用于制备这种化合物的中间体，制备这种化合物，含有这种化合物的药物组合物，抑制JAK活性的方法，以及预防或治疗至少部分由JAK活性介导的多种疾病的方法。
• NICOTINAMIDES AS JAK KINASE MODULATORS
  申请人：Bauer Shawn M.

  公开号：US20120108566A1

  公开（公告）日：2012-05-03

  The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及具有公式I的化合物及其药用可接受的盐、酯和前药，这些化合物是JAK激酶的抑制剂。本发明还涉及用于制备这类化合物的中间体，该化合物的制备，含有该化合物的药物组合物，抑制JAK激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由JAK激酶活性介导的多种疾病条件的方法，例如不良血栓形成和非霍奇金淋巴瘤。
• Process for preparing 2,4- dihydroxypyridine and 2,4- dihydroxy-3-nitropyridine
  申请人：Aventis Pharmaceuticals Products Inc.

  公开号：US06307054B1

  公开（公告）日：2001-10-23

  The present invention is directed to a process for preparing 2,4-dihydroxy-pyridine comprising heating a compound of the formula A wherein R is H, alkyl or aralkyl and phosphoric acid where the ratio of phosphoric acid to water is not less than about 27 to 1 weight %. The invention is also directed to a process for preparing 2,4-dihydroxy-3-nitropyridine comprising reacting 2,4-dihydroxypyridine with nitric acid. The processes of the present invention prepare intermediates which are useful in preparing compounds which are useful for treating cardiovascular disease marked by hypertension or myocardial ischemia, ameliorating ischenic injury or myocardial infarct size, or treating hyperlipidemia or hypercholesterolemia.

  本发明涉及一种制备2,4-二羟基吡啶的方法，包括加热化合物A的过程，其中化合物A的结构式为R为H、烷基或芳基，以及磷酸，其中磷酸与水的比例不少于27:1重量%。该发明还涉及一种制备2,4-二羟基-3-硝基吡啶的方法，包括将2,4-二羟基吡啶与硝酸反应。本发明的方法制备的中间体可用于制备用于治疗高血压或心肌缺血所致心血管疾病、改善缺血损伤或心肌梗死大小的化合物，或用于治疗高脂血症或高胆固醇血症。
• Process for preparing 2,4-dihydroxypyridine and 2,4-dihydroxy-3-nitropyridine
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US06392049B1

  公开（公告）日：2002-05-21

  The present invention is directed to a process for preparing 2,4-dihydroypyridine comprising heating a compound of the formula A wherein R is H, alkyl or aralkyl and phosphoric acid where the ratio of phosphoric acid to water is not less than about 27 to 1 weight %. The invention is also directed to a process for preparing 2,4-dihydroy-3-nitropyridine comprising reacting 2,4-dihydroypyridine with nitric acid. The processes of the present invention prepare intermediates which are useful in preparing compounds which are useful for treating cardiovascular disease marked by hypertension or myocardial ischeria, ameliorating ischemic injury or myocardial infarct size, or treating hyperlipidemia or hypercholesterolemia.

  本发明涉及一种制备2,4-二氢吡啶的方法，包括加热化合物A式，其中R为H、烷基或芳基烷基，和磷酸，其中磷酸与水的比例不少于27:1重量%。本发明还涉及一种制备2,4-二氢-3-硝基吡啶的方法，包括将2,4-二氢吡啶与硝酸反应。本发明的过程制备的中间体在制备用于治疗心血管疾病的化合物中有用，其中该疾病以高血压或心肌缺血为特征，改善缺血性损伤或心肌梗死大小，或治疗高脂血症或高胆固醇血症。
• INHIBITORS OF JAK
  申请人：Portola Pharmaceuticals, Inc.

  公开号：US20130137673A1

  公开（公告）日：2013-05-30

  The present invention is directed to compounds of formula I and tautomers and pharmaceutically acceptable salts thereof which are selective inhibitors of JAK. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK activity, and methods to prevent or treat a number of conditions mediated at least in part by JAK activity.

  本发明涉及公式I的化合物及其互变异构体和药学上可接受的盐，其为选择性JAK抑制剂。本发明还涉及制备此类化合物所使用的中间体、制备此类化合物的方法、包含此类化合物的药物组合物、抑制JAK活性的方法，以及预防或治疗至少部分由JAK活性介导的多种疾病的方法。